The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: A cross-sectional study

Pharmacogenomics Journal

Volumn 7, Issue 5, 2007, Pages 318-324

  Mulder, H ^a,b   Franke, B ^c   Aart van der Beek van der, A ^d   Arends, J ^e   Wilmink, F W ^e   Egberts, A C G ^a,f   Scheffer, H ^c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Wilhelmina Ziekenhuis   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MARTINI HOSPITAL   (Netherlands)

^e Mental Health Centre Drenthe   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BROMPERIDOL; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SEROTONIN 2C RECEPTOR; THIORIDAZINE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OBESITY; PRIORITY JOURNAL; PROMOTER REGION; RISK ASSESSMENT; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTRONS; LINKAGE DISEQUILIBRIUM; LOGISTIC MODELS; MALE; MIDDLE AGED; OBESITY; ODDS RATIO; PATIENT SELECTION; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); PSYCHOTIC DISORDERS; RECEPTOR, SEROTONIN, 5-HT2C; RISK ASSESSMENT; RISK FACTORS; SCHIZOPHRENIA;

EID: 34748854911     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500422     Document Type: Article

References (27)

1. Allison DB, Casey DE. Antipsychotic-induced weight gain: A review of the literature. J Clin Psychiatry 2001; 62(Suppl 7): 22-31.
2. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999; 282: 1523-1529.
3. Allison DB, Fontaine KR, Manson JE, Stevens J, VanItallie TB. Annual deaths attributable to obesity in the United States. JAMA 1999; 282: 1530-1538.
4. Muller DJ, Muglia P, Fortune T, Kennedy JL. Pharmacogenetics of antipsychotic-induced weight gain. Pharmacol Res 2004; 49: 309-329.
5. Hugenholtz GW, Heerdink ER, Meijer WE, Stolker JJ, Egberts AC, Nolen WA. Reasons for switching between antipsychotics in daily clinical practice. Pharmacopsychiatry 2005; 38: 122-124.
6. Yuan X, Yamada K, Ishiyama-Shigemoto S, Koyama W, Nonaka K. Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type II diabetes. Diabetologia 2000; 43: 373-376.
7. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002; 359: 2086-2087.
8. Reynolds GP, Zhang Z, Zhang X. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry 2003; 160: 677-679.
9. Templeman LA, Reynolds GP, Arranz B, San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 2005; 15: 195-200.
10. Ellingrod VL, Perry PJ, Ringold JC, Lund BC, Bever-Stille K, Fleming F et al. Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B 2005; 134: 76-78.
11. Miller dD, Ellingrod VL, Holman TL, Buckley PF, Arndt S. Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism. Am J Med Genet B 2005; 133: 97-100.
12. Theisen FM, Hinney A, Bromel T, Heinzel-Gutenbrunner M, Martin M, Krieg JC et al. Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals. Psychiatr Genet 2004; 14: 139-142.
13. Ellingrod VL, Miller D, Ringold JC, Perry PJ. Distribution of the serotonin 2C (5HT2C) receptor gene -759C/T polymorphism in patients with schizophrenia and normal controls. Psychiatr Genet 2004; 14: 93-95.
14. Tsai SJ, Hong CJ, Yu YW, Lin CH. 759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet 2002; 360 1790.
15. Basile VS, Masellis M, De Luca V, Meltzer HY, Kennedy JL. 759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet 2002; 360: 1790-1791.
16. Reynolds GP, Templeman LA, Zhang ZJ. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 1021-1028.
17. Pooley EC, Fairburn CG, Cooper Z, Sodhi MS, Cowen PJ, Harrison PJ. A 5-HT2C receptor promoter polymorphism (HT). Am J Med Genet B 2004; 126: 124-127.
18. McCarthy S, Mottagui-Tabar S, Mizuno Y, Sennblad B, Hoffstedt J, Arner P et al. Complex HTR2C linkage disequilibrium and promoter associations with body mass index and serum leptin. Hum Genet 2005; 117: 545-557.
19. Perneger TV. What's wrong with Bonferroni adjustments. BMJ 1998; 316: 1236-1238.
20. Blin O, Micallef J. Antipsychotic-associated weight gain and clinical outcome parameters. J Clin Psychiatry 2001; 62(Suppl 7): 11-21.
21. Ronaghi M, Uhlen M, Nyren P. A sequencing method based on realtime pyrophosphate. Science 1998; 281: 363-365.
22. Pacey-Miller T, Henry R. Single-nucleotide polymorphism detection in plants using a single-stranded pyrosequencing protocol with a universal biotinylated primer. Anal Biochem 2003; 317: 166-170.
23. Anonymous. Anatomical Therapeutic Chemical (ATC) Classification Index: Including Defined Daily Doses (DDDs) for Plain Substances. World Health Organization: Oslo, Norway, 1997.
24. Vanina Y, Podolskaya A, Sedky K, Shahab H, Siddiqui A, Munshi F et al. Body weight changes associated with psychopharmacology. Psychiatr Serv 2002; 53: 842-847.
25. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002; 63: 856-865.
26. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21 263-265.
27. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993; 138: 923-936.